Leading diagnostic chain Dr Lal PathLabs has filed draft red herring prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) to raise funds through an IPO. The promoters and other existing shareholders will collectively sell 11.6 million shares of the company amounting to 14.1 per cent stake.
As per the DRHP, the IPO would be made through an Offer for Sale and the proceeds would be remitted to the respective promoters and other investors and therefore the company will not receive any proceeds from the offer.
Kotak Mahindra Capital and Citigroup Global Markets India are the book running lead managers for the IPO.
Dr Lalpathlabs is a pioneer diagnostic centre in India that provides blood test services. It is believed to be the most trusted pathology lab in the country.
| Company Name | CMP |
|---|---|
| Apollo Hospital Ent. | 7830.05 |
| Max Healthcare Inst | 1007.05 |
| Narayana Hrudayalay | 1808.95 |
| Aster DM Healthcare | 689.30 |
| Global Health | 1109.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: